Neurology & Pain Management Coding Alert

Reader Question:

Only 715.16 Eases Synvisc Injection Coding

Question: A new physician in our office wants to administer Synvisc knee injections for our mostly-Medicare patient population. A Medicare representative told me that national and local coverage determinations (NCDs/ LCDs) are nonexistent and that we simply have to prove medical necessity. What diagnoses work or don't work?New Jersey SubscriberAnswer: Currently, Synvisc (hyaluronan) injections are only approved by the FDA to treat osteoarthritis of the knee. You report diagnosis 715.16 (Osteoarthrosis, localized, primary; lower leg).The Medicare representative you spoke to is correct in saying Medicare does not have an NCD addressing the hyaluronan articular biologics. Many LCDs on the subject exist, however, and many commercial payers also have coverage policies addressing the treatment. Some have guidelines regarding conservative therapies the physician should document before administering hyaluronon injections. Check each payer's coverage policy before beginning treatments.Tip: Some non-Medicare payers might require you to order Synvisc from a specialty pharmacy. Research this [...]
You’ve reached your limit of free articles. Already a subscriber? Log in.
Not a subscriber? Subscribe today to continue reading this article. Plus, you’ll get:
  • Simple explanations of current healthcare regulations and payer programs
  • Real-world reporting scenarios solved by our expert coders
  • Industry news, such as MAC and RAC activities, the OIG Work Plan, and CERT reports
  • Instant access to every article ever published in your eNewsletter
  • 6 annual AAPC-approved CEUs*
  • The latest updates for CPT®, ICD-10-CM, HCPCS Level II, NCCI edits, modifiers, compliance, technology, practice management, and more
*CEUs available with select eNewsletters.